Related Experiment Videos
Recent status of the antisense oligonucleotide approaches in oncology
1Laboratoire de Pharmacologie Expérimentale et Clinique, Hôpital Saint Louis, Paris, France.
Abstract:
Antisense oligonucleotides designed to complement a region of a particular messenger RNA may inhibit gene expression potentially through sequence-specific hybridization. Their inhibiting effect has been shown in a variety of in vitro and in vivo models in oncology, whereas much rarer clinical trials have been carried out. Rigorous demonstration of in vitro and in vivo specific effects upon their targets is mandatory before their use as drugs in cancer therapy.
Insights
Antisense oligonucleotides can inhibit gene expression by targeting messenger RNA. Rigorous in vitro and in vivo validation is essential before using these compounds as cancer therapeutics.
Area of Science:
- Molecular Biology
- Pharmacology
- Oncology
Background:
- Antisense oligonucleotides (ASOs) are short nucleic acid sequences designed to bind to specific messenger RNA (mRNA) molecules.
- This binding can modulate gene expression, offering a potential therapeutic strategy.
Purpose of the Study:
- To review the potential of antisense oligonucleotides in cancer therapy.
- To emphasize the necessity of rigorous validation for their clinical application.
Main Methods:
- Literature review of in vitro and in vivo studies involving antisense oligonucleotides in oncology.
- Analysis of existing clinical trial data, where available.
Main Results:
- Antisense oligonucleotides have demonstrated efficacy in inhibiting gene expression in various preclinical cancer models.
- Clinical applications and trials remain less common compared to preclinical research.
Conclusions:
- Sequence-specific hybridization by antisense oligonucleotides offers a promising mechanism for gene expression inhibition in cancer.
- Mandatory rigorous demonstration of specific in vitro and in vivo effects is crucial for the development of ASOs as cancer drugs.